Deep learning for prediction of colorectal cancer outcome: a discovery and validation study
暂无分享,去创建一个
Marco Novelli | Fritz Albregtsen | Ian Tomlinson | John Maddison | Håvard E Danielsen | Rachel Kerr | Knut Liestøl | Enric Domingo | D. Kerr | K. Liestøl | F. Albregtsen | I. Tomlinson | M. Novelli | H. Danielsen | A. Nesbakken | E. Domingo | M. Pradhan | A. Kleppe | T. Hveem | I. Farstad | D. Church | R. Kerr | O. Skrede | S. D. Raedt | J. Maddison | H. Askautrud | J. A. Nesheim | N. Shepherd | Andreas Kleppe | Manohar Pradhan | Tarjei S Hveem | Hanne A Askautrud | Arild Nesbakken | David J Kerr | John Arne Nesheim | Ole-Johan Skrede | Sepp De Raedt | Inger Nina Farstad | David N Church | Neil A Shepherd | Andreas Kleppe
[1] N. Razavian,et al. Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning , 2018, Nature Medicine.
[2] A. Briggs,et al. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial , 2018, The Lancet. Oncology.
[3] R. Labianca,et al. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer , 2018, The New England journal of medicine.
[4] Jeffrey A. Moscow,et al. The evidence framework for precision cancer medicine , 2018, Nature Reviews Clinical Oncology.
[5] Dmitrii Bychkov,et al. Deep learning based tissue analysis predicts outcome in colorectal cancer , 2018, Scientific Reports.
[6] I Tomlinson,et al. Prognostic markers for colorectal cancer: estimating ploidy and stroma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] D. Brat,et al. Predicting cancer outcomes from histology and genomics using convolutional networks , 2017, Proceedings of the National Academy of Sciences.
[8] Andrew H. Beck,et al. Diagnostic Assessment of Deep Learning Algorithms for Detection of Lymph Node Metastases in Women With Breast Cancer , 2017, JAMA.
[9] Wei Luo,et al. Guidelines for Developing and Reporting Machine Learning Predictive Models in Biomedical Research: A Multidisciplinary View , 2016, Journal of medical Internet research.
[10] D. Kerr,et al. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. , 2016, The Lancet. Oncology.
[11] Brendan J. Frey,et al. Classifying and segmenting microscopy images with deep multiple instance learning , 2015, Bioinform..
[12] C. Tournigand,et al. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Adam Kiezun,et al. Whole-exome sequencing and clinical interpretation of FFPE tumor samples to guide precision cancer medicine , 2013, Nature Medicine.
[14] C. Yau,et al. Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations , 2013, The American Journal of Gastroenterology.
[15] D. Kerr,et al. Biological markers: Tailoring treatment and trials to prognosis , 2013, Nature Reviews Clinical Oncology.
[16] Douglas G Altman,et al. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration , 2012, BMC Medicine.
[17] D. Kerr,et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] D. Kerr,et al. Predictive biomarkers: a paradigm shift towards personalized cancer medicine , 2011, Nature Reviews Clinical Oncology.
[19] D. Kerr,et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] L. V. van't Veer,et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] N. Shepherd,et al. How important is peritoneal involvement in rectal cancer? A prospective study of 331 cases , 2010, Histopathology.
[22] D. Kerr,et al. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] F. Sinicrope. DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer , 2010, Nature Reviews Clinical Oncology.
[24] T. Hickish,et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Dongsheng Tu,et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.
[26] Quasar Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study , 2007, The Lancet.
[27] J. Nesland,et al. Expression and gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome , 2005, Journal of Clinical Pathology.
[28] N. Shepherd,et al. Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer , 2002, Gut.
[29] D. Kerr,et al. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial , 2000, The Lancet.